Prix
Questions fréquentes
Quelle est la capitalisation boursière de Summit ?
Quel est le bénéfice par action (BPA) de Summit ?
Quelles sont les évaluations des analystes et le prix cible de l'action Summit ?
Quel est l'EBITDA de Summit ?
Quel est le flux de trésorerie disponible de Summit ?
Quel est le bêta à 5 ans de l'action Summit ?
Combien d'employés compte Summit, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Summit ?
Finances
Capitalisation boursière
16,05 Md $USbêta sur 5 ans
-0,88BPA (TTM)
-0,277 $USFree Float
115,30 MEBITDA (TTM)
-181,49 M $USCash-flow disponible (TTM)
-113,02 M $USCotation
Notes des analystes
L'objectif de prix est de 13,50 $US et l'action est analysée par 2 analystes.
Acheter
2
Hold
0
Vendre
0
Informations
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
105
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire